Protein drug formulations and packages
Compositions and methods that include stabilized protein drugs are described. In addition, protein drug formulations that are more stable under ambient conditions are described. The formulations include one or more poly amino acid ligands of the protein drug.
1. A pharmaceutical composition suitable for delivery to a patient comprising:
a mixed human IgG having an Fc domain; and
a protein A fragment consisting of sequences selected from the group consisting of FNKEQQNAFYEIL (SEQ ID NO:3) and EQRNGFIQSLKD (SEQ ID NO:4), wherein the mixed human IgG is bound to the protein A fragment via the Fc domain and is substantially free of IgG aggregates, wherein the ratio of mixed human IgG to the protein A fragment is approximately 1:4.
2. A pharmaceutical composition comprising:
a protein drug having an Fc domain; and
a polyamino acid ligand consisting of FNKEQQNAFYEIL (SEQ ID NO:3), or a polyamino acid ligand consisting of EQRNGFIQSLKD (SEQ ID NO:4), wherein the ratio of the protein drug to the polyamino acid ligand is approximately 1:4 wherein the polyamino acid ligand is bound to the Fc domain of the protein drug and the protein drug exhibits reduced aggregation as compared to the protein drug alone.
3. The pharmaceutical composition comprising of claim 2 , wherein the pharmaceutical composition is a solution.
4. The pharmaceutical composition comprising of claim 2 , wherein the protein drug is mixed human IgG.
5. The pharmaceutical composition comprising of claim 2 , wherein the protein drug is IgG1, IgG2 or an immunoglobulin G-like protein.
6. The pharmaceutical composition comprising of claim 2 , wherein the polyamino acid ligand is non-immunogenic.
7. A pharmaceutical composition comprising:
a protein drug having an Fc domain; and
a polypeptide consisting of 13 to 50 amino acids that comprises a polyamino acid ligand consisting of FNKEQQNAFYEIL (SEQ ID NO:3),
wherein the ratio of the protein drug to the polyamino acid ligand is approximately 1:4, wherein the polyamino acid ligand is bound to the Fc domain of the protein drug, and wherein the protein drug exhibits reduced aggregation as compared to the protein drug alone.
8. A pharmaceutical composition comprising:
a protein drug having an Fc domain; and
a polypeptide consisting of 12 to 50 amino acids that comprises a polyamino acid ligand consisting of EQRNGFIQSLKD (SEQ ID NO:4),
wherein the ratio of the protein drug to the polyamino acid ligand is approximately 1:4, wherein the polyamino acid ligand is bound to the Fc domain of the protein drug, and wherein the protein drug exhibits reduced aggregation as compared to the protein drug alone.
9. A method of stabilizing a protein drug, the method comprising:
contacting a free protein drug having an Fc domain with a free polyamino acid ligand that binds to the Fc domain, wherein the ratio of protein drug to the polyamino acid ligand is approximately 1:4, thereby creating a stabilized protein drug exhibiting a reduced formation of aggregates as compared to the free protein drug, wherein said polyamino acid ligand consists of sequences selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
10. The method of claim 9 , wherein the protein drug is mixed human IgG, IgG1, IgG2 or an immunoglobulin G-like protein.
11. A method of stabilizing a protein drug, the method comprising:
contacting a free protein drug having an Fc domain with a free polypeptide consisting of 13 to 50 amino acids that comprises a polyamino acid ligand consisting of FNKEQQNAFYEIL (SEQ ID NO:3), or
contacting a free protein drug having an Fc domain with a free polypeptide consisting of 12 to 50 amino acids that comprises a polyamino acid ligand consisting of EQRNGFIQSLKD (SEQ ID NO:4),
wherein the polyamino acid ligand binds to the Fc domain, and wherein the ratio of protein drug to the polyamino acid ligand is approximately 1:4, thereby creating a stabilized protein drug exhibiting a reduced formation of aggregates as compared to the free protein drug alone.
12. The method of claim 11 , further comprising contacting the stabilized protein drug with a releasing agent, the releasing agent causing the polyamino acid ligand to disassociate from the Fc domain.
13. The method of claim 12 , where the releasing agent comprises glycine, a competitive ligand for the polyamino acid ligand, an acid, or an acidic buffer.
14. The method of claim 9 , further comprising agitating the stabilized protein drug, wherein the stabilized protein drug remains substantially free of aggregates following the agitating.
15. The method of claim 14 , wherein the agitating comprising shaking for at least 24 hours.
16. The method of claim 14 , wherein at least 50% of the stabilized protein drug is soluble protein following the agitating.
17. The method of claim 16 , wherein at least 90% of the stabilized protein drug is soluble protein following the agitating.
18. A pharmaceutical composition suitable for long term storage comprising:
a protein drug having an Fc domain; and
a polyamino acid ligand comprising an epitope sequence of FNKEQQNAFYEIL (SEQ ID NO:3), or a polyamino acid ligand comprising an epitope sequence of EQRNGFIQSLKD (SEQ ID NO:4), wherein the polyamino acid ligand is further releasably embedded in a polymer backbone and bound to the Fc domain of the protein drug.
19. The pharmaceutical composition according to claim 18 , wherein the polymer backbone is a polyalkylene glyocol or a polyoxyalkylene.
20. The pharmaceutical composition according to claim 18 further comprising an stabilizing excipient on a solid surface to immobilize the polyamino acid ligand bound protein drug, wherein said stabilizing excipient covalently binds to the polyamino acid ligand.